ReviewFrontiers in pharmacology2021
Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Mechanisms of Paclitaxel Resistance: Recent Advances and Future Perspectives.International journal of molecular sciences · 2026Review
- Autophagy activation by urolithin-a derivative UA-36 mitigates Friedreich's ataxia pathologies induced by frataxin deficiency.Molecular biomedicine · 2026Article
- Autophagy-Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting.Cancers · 2026Review
- Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway.Immunity, inflammation and disease · 2026Article
- Therapeutic potential and molecular mechanisms of Yi-Yi-Fu-Zi-Bai-Jiang-San in the treatment of colorectal cancer.Frontiers in pharmacology · 2026Review
- Lysosome-dependent cell death in hepatocellular carcinoma: unlocking the therapeutic potential of natural products.Frontiers in pharmacology · 2026Review
- Artificial intelligence driven multi-omics framework identifies COL6A3 as a diagnostic biomarker and a putative gene target modulated by Embelin in Colorectal cancer.Frontiers in oncology · 2026Article
- Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
- Pharmacological insights and role of bufalin (bufadienolides) in inflammation modulation: a narrative review.Inflammopharmacology · 2024Review
- Review
- Magnolol promotes the autophagy of esophageal carcinoma cells by upregulatingActa biochimica et biophysica Sinica · 2024Article
- Immunomodulatory and chemopreventive effects of resveratrol on the digestive system cancers.Oncology research · 2024Review
- Sakurasosaponin inhibits lung cancer cell proliferation by inducing autophagy via AMPK activation.Oncology letters · 2023Article
- Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.Biomedicines · 2023Review
- Inhibition of Autophagy Increases Cell Death in HeLa Cells through Usnic Acid Isolated from Lichens.Plants (Basel, Switzerland) · 2023Article
- Review
- Polyphyllin II induced apoptosis of NSCLC cells by inhibiting autophagy through the mTOR pathway.Pharmaceutical biology · 2022Article
- Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective.Biomolecules · 2022Review
- The Effects of Resveratrol-Rich Extracts ofPharmaceutics · 2022Article
- Screening of Apoptosis Pathway-Mediated Anti-Proliferative Activity of the Phytochemical Compound Furanodienone against Human Non-Small Lung Cancer A-549 Cells.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products are well-characterized to have pharmacological or biological activities that can be of therapeutic benefits for cancer therapy, which also provide an important source of inspiration for discovery of potential novel small-molecule drugs. In the past three decades, accumulating evidence has revealed that natural products can modulate a series of key autophagic signaling pathways and display therapeutic effects in different types of human cancers. In this review, we focus on summarizing some representative natural active compounds, mainly including curcumin, resveratrol, paclitaxel, Bufalin, and Ursolic acid that may ultimately trigger cancer cell death through the regulation of some key autophagic signaling pathways, such as RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, AMPK, ULK1, Beclin-1, Atg5 and p53. Taken together, these inspiring findings would shed light on exploiting more natural compounds as candidate small-molecule drugs, by targeting the crucial pathways of autophagy for the future cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.